Physician profile
Philip Leigh Withnell
NPI 1326097288
$3,704.42
in general payments reported to CMS, 2019-2025
39 companies · $698 in 2025
The $698 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $392 · 2021: $902 · 2022: $286 · 2023: $465 · 2024: $409 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $712.53 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $216.86 | 2019-2023 | |
| Novo Nordisk INC | $209.59 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $206.28 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $203.26 | 2020-2025 | Invega, Spravato |
| Exact Sciences Corporation | $185.02 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $172.88 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Xeris Pharmaceuticals, INC. | $144.89 | 2024-2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $140.84 | 2021-2025 | Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $129.98 | 2019-2025 | Gardasil 9, Vaxneuvance, Enflonsia |
| Vanda Pharmaceuticals INC. | $106.07 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $103.90 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.69 | 2025 | Caplyta |
| Allergan, INC. | $90.38 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.96 | 2019-2023 | Jardiance |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Withnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.